Palisade Bio Q2 net loss widens to $10.6 million as Phase 2 spending rises
Palisade Bio reported second-quarter 2026 results, with a net loss of $10.6 million, up from $2.8 million a year earlier, as research and development and general and administrative expenses rose sharply. The company is preparing to start the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026, and it had $125.2 million in cash and cash equivalents as of June 30, 2026.
Key points
- Net loss was $10.6 million, or $0.05 per share, for the three months ended June 30, 2026, versus $2.8 million, or $0.58 per share, a year earlier.
- Research and development expenses rose to $7.4 million from $1.7 million, and general and administrative expenses rose to $4.8 million from $1.2 million.
- License revenue of $0.5 million was recognized from a milestone under the Newsoara co-development agreement; none was recognized in the prior-year quarter.
- Cash and cash equivalents were $125.2 million at June 30, 2026, which the company says should fund operations through its key Phase 2 readouts, expected in the second half of 2027 and early 2028.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.